Sanofi
SNYNFDrugs in Pipeline
186
Phase 3 Programs
117
Upcoming Catalysts
5
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
5 upcoming, 0 past
Amlitelimab Phase 2 Est. Readout
Primary completion for Amlitelimab trial (NCT06557772) in Coeliac Disease
Source4 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
SSR591813L (dianicline)
Smoking Cessation
DTaP-IPV-HB-PRP~T vaccine
Diphtheria
Semuloparin sodium
Venous Thromboembolism
Lactic acid (Dermacid)
Hygiene
Dermacyd Femina Pocket BR (Lactic Acid)
Hygiene
Ramipril
Glomerulonephritis
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)
Meningococcal Immunisation (Healthy Volunteers)
HOE901-U300 (new formulation of insulin glargine)
Type 2 Diabetes Mellitus
hydroxychloroquine
Rheumatoid Arthritis
Teriflunomide
Multiple Sclerosis
Cetylpyridinium chloride
Healthy
SR34006 (idraparinux sodium) Injection
Atrial Fibrillation
Lipid-Modifying Therapy (LMT)
Hypercholesterolemia
Lunsekimig
Chronic Obstructive Pulmonary Disease
telithromycin (HMR3647)
Infections
Clopidogrel (SR25990)
Acute Coronary Syndromes
Vandetanib
Thyroid Neoplasms
Lactic Acid
Hygiene
Sarilumab SAR153191
Corona Virus Infection
Sevelamer carbonate (Renvela®)
Chronic Kidney Disease
Telithromycin
Asthma
Insulin glargine U100 (HOE901)
Type 2 Diabetes Mellitus
Granulocyte colony-stimulating factor plus plerixafor
Multiple Myeloma
clopidogrel (SR25990C)
Platelet Aggregation Inhibitors
Docetaxel (TAXOTERE®) Chemotherapy
Prostatic Neoplasms
Fitusiran
Hemophilia
Insulin glargine (HOE901)
Type 2 Diabetes
Itepekimab (SAR440340)
Chronic Rhinosinusitis With Nasal Polyps
insulin lispro
Diabetes Mellitus, Insulin-Dependent
gemcitabine
Urinary Bladder Neoplasms
Saredutant
Depressive Disorder
rilzabrutinib
Immune Thrombocytopenia
Tolebrutinib
Relapsing Multiple Sclerosis
Insulin glulisine
Diabetes Mellitus, Type 1
Rimonabant
Diabetes Mellitus, Type 2
sarilumab SAR153191 (REGN88)
Rheumatoid Arthritis
Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Meningococcal Infection (Healthy Volunteers)
Cisplatin
Nasopharyngeal Neoplasms
Dupilumab SAR231893 (REGN668)
Asthma
Saredutant succinate (SR48968C)
Depressive Disorder
Alemtuzumab
Multiple Sclerosis, Relapsing-Remitting
5-FLUOROURACIL
Head and Neck Neoplasms
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Neoplasms
Insulin glargine
Diabetes Mellitus, Type 1
Duvakitug
Crohn's Disease
Xaliproden (SR57746A)
Metastases
SR48692
Lung Cancer
efanesoctocog alfa (BIVV001)
Factor VIII Deficiency
gemcitabine/carboplatin
Breast Cancer
ZD6474 (vandetanib)
Non-Small-Cell Lung Carcinoma
Cabazitaxel (XRP6258)
Prostate Cancer
Enoxaparin sodium (XRP4563)
Myocardial Infarction
Artesunate + Amodiaquine
Malaria
Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
Hygiene
fexofenadine/Allegra (M016455)
Rhinitis Perennial
Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Healthy Volunteers (Meningococcal Infection)
MenACYW conjugate vaccine
Meningococcal Immunisation
Lipid Modifying Therapy (LMT)
Hypercholesterolaemia
tolevamer potassium-sodium (GT267-004)
Pseudomembranous Colitis
Aflibercept
Colorectal Cancer Metastatic
Iniparib
Breast Cancer, Metastatic
Influenza virus vaccine (split virion, inactivated)
Influenza
ALIROCUMAB SAR236553 (REGN727)
Hypercholesterolemia
dronedarone (SR33589)
Atrial Fibrillation
Amlitelimab
Asthma
Sitagliptin
Type 2 Diabetes Mellitus
Insulin glargine/Lixisenatide (HOE901/AVE0010)
Type 2 Diabetes Mellitus
PCV21
Sickle Cell Disease
Metformin
Diabetes Mellitus, Type 2
Clopidogrel
Ischemia
Teriflunomide (HMR1726)
Multiple Sclerosis
Insulin glargine/lixisenatide Fixed Ratio Combination
Type 2 Diabetes
Irbesartan
Atrial Fibrillation
teriflunomide HMR1726
Multiple Sclerosis
Mitoxantrone
Prostatic Neoplasms
rhIDU (recombinant human-Alpha-L-Iduronidase)
Mucopolysaccharidosis I
escitalopram
Major Depressive Disorder
SR121463B
Inappropriate ADH Syndrome
Olipudase alfa
Sphingomyelin Lipidosis
Myozyme
Glycogen Storage Disease Type II
Itepekimab SAR440340
Chronic Obstructive Pulmonary Disease
Insulin glulisine QD
Type 2 Diabetes
Enoxaparin sodium
Percutaneous Coronary Intervention
Ciclesonide (XRP1526)
Asthma
Yellow fever vaccine (live)
Yellow Fever
Dermacyd PH_DETINLYN (Lactic Acid)
Hygiene
Lixisenatide (AVE0010)
Type 2 Diabetes Mellitus
LACTIC ACID(ND)
Hygiene
Insuline glulisine
Diabetes Mellitus, Type 1
Rimonabant (SR141716)
Obesity
amibegron (SR58611A)
Major Depressive Disorders
Alfuzosin
Prostatic Hyperplasia
Eliglustat tartrate
Gaucher Disease, Type 1
SR58611A
Depressive Disorder
Larotaxel (XRP9881)
Pancreatic Neoplasms
lactoserum
Hygiene
NVX-CoV2705
COVID-19
Lispro
Diabetes Mellitus
cabazitaxel (XRP6258) (RPR116258)
Neoplasms
Thyrogen + Radioiodine (131I)
Thyroid Neoplasms
alfuzosin (SL770499)
Urinary Bladder Neurogenic
Alirocumab
Hypercholesterolemia
ezetimibe
Hypercholesterolemia
Caplacizumab
Acquired Thrombotic Thrombocytopenic Purpura
Glimepiride
Diabetes Mellitus, Non-Insulin-Dependent
Docetaxel
Lung Neoplasms
Fexofenadine
Asthma
Dupilumab
Chronic Spontaneous Urticaria
Enoxaparin
Venous Thromboembolism
Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib
Diphtheria
leflunomide
Arthritis, Rheumatoid
Sarilumab
Rheumatoid Arthritis
Dupilumab SAR231893
Chronic Rhinosinusitis Without Nasal Polyps
INSULIN GLARGINE (U300)
Type 2 Diabetes Mellitus
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine
Healthy Volunteers (Meningococcal Infection)
Dermacyd PH_DETINBACK (Lactic Acid)
Hygiene
Isatuximab SAR650984
Plasma Cell Myeloma
SAR3419
Diffuse Large B-cell Lymphoma
XRP0038 (NV1FGF)
Peripheral Arterial Occlusive Disease
DOCETAXEL XRP6976
Squamous Cell Carcinoma of Head and Neck
Inactivated, Split-Virion Influenza Virus
Influenza
Split, Inactivated, Trivalent Influenza Vaccine
Orthomyxoviridae Infection
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
Systemic Sclerosis
Levofolinate
Colorectal Cancer Metastatic
clofarabine (IV formulation)
Acute Myelogenous Leukemia
Swine A/H1N1 influenza vaccine (split virion, inactivated)
Influenza
Liraglutide
Type 2 Diabetes Mellitus
ataciguat (HMR1766)
Pain
A/H5N1 inactivated, split-virion influenza virus
Influenza
Thymoglobulin [Anti-thymocyte Globulin (rabbit)]
Cadaveric Donor Renal Transplantation
RISEDRONATE
OSTEOPOROSIS, POSTMENOPAUSAL
Oxaliplatin (SR96669)
Gastrointestinal Cancer
plerixafor
Ewing's Sarcoma/Soft Tissue Sarcoma
G-CSF Plus Plerixafor
Lymphoma, Non-Hodgkin
frexalimab
Focal Segmental Glomerulosclerosis
XL147 (SAR245408)
Breast Cancer
Fluticasone/Salmeterol combination therapy
Asthma
SAR443122
Cutaneous Lupus Erythematosus
Alglucosidase alfa
Glycogen Storage Disease Type II
Isatuximab
Relapsed/Refractory Multiple Myeloma
Teplizumab
Type 1 Diabetes Mellitus
BSI-201
Ovarian Cancer
Doxercalciferol
Moderate to Severe Chronic Plaque Psoriasis
Atorvastatin
Hypercholesterolemia
SSR149415
Anxiety Disorders
venglustat (GZ402671)
Gaucher Disease Type 1
SAR245409
Lymphoma
ILX651
Hormone-refractory Prostate Cancer
cabazitaxel XRP6258
Gastric Cancer
Inactivated, split-virion influenza vaccine
Influenza
Avalglucosidase Alfa
Glycogen Storage Disease Type II Pompe Disease
SAR156597
Systemic Sclerosis
Ad2/HIF-1α/VP16
Intermittent Claudication
SR57667B
Parkinson Disease
Oxaliplatin
Stomach Neoplasms
Belumosudil
Chronic Graft Versus Host Disease
RSVt Vaccine
Respiratory Syncytial Virus Infection
Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine
Meningitis
Acne mRNA vaccine
Acne
SAR441566
Psoriasis
Fabrazyme (agalsidase beta)
Fabry Disease
satavaptan (SR121463B)
Ascites
eplivanserin (SR46349)
Fibromyalgia
ombrabulin (AVE8062)
Non-small Cell Lung Cancer
Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant
Influenza
Oxaliplatin, 5-FU
Head and Neck Cancer
rasburicase (SR29142)
Nutritional and Metabolic Diseases
Fludarabine Phosphate (Fludara)
Non Hodgkin Lymphoma
GZ/SAR402671
Fabry Disease
Influenza Virus Vaccine USP Trivalent Types A and B
Influenza
ZD6474, Vandetanib
Biliary Tract Cancer
Mometasone furoate nasal spray
Nasal Polyps
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Mucopolysaccharidosis I
ATN-103
Active Rheumatoid Arthritis
CYD Dengue Vaccine
Dengue
plerixafor GZ316455
Lymphoma
clofarabine
Acute Myelogenous Leukemia
Sevelamer carbonate
Hyperphosphatemia
Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine
Lung Neoplasms
Capecitabine
Rectal Neoplasms
SAR442970
Ulcerative Colitis
Nerispirdine
Multiple Sclerosis
ZD6474
Breast Neoplasms
Methotrexate
Rheumatoid Arthritis
ALX-0061
Rheumatoid Arthritis
docetaxel (XRP6976)
Therapy, Prostatic Neoplasms
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SSR591813L (dianicline) | Phase 3 | Smoking Cessation | - | - |
DTaP-IPV-HB-PRP~T vaccine | Phase 3 | Diphtheria | - | - |
Semuloparin sodium | Phase 3 | Venous Thromboembolism | - | - |
Lactic acid (Dermacid) | Phase 3 | Hygiene | - | - |
Dermacyd Femina Pocket BR (Lactic Acid) | Phase 3 | Hygiene | - | - |
Ramipril | Phase 3 | Glomerulonephritis | - | - |
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine) | Phase 3 | Meningococcal Immunisation (Healthy Volunteers) | - | - |
HOE901-U300 (new formulation of insulin glargine) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
hydroxychloroquine | Phase 3 | Rheumatoid Arthritis | - | - |
Teriflunomide | Phase 3 | Multiple Sclerosis | - | - |
Cetylpyridinium chloride | Phase 3 | Healthy | - | - |
SR34006 (idraparinux sodium) Injection | Phase 3 | Atrial Fibrillation | - | - |
Lipid-Modifying Therapy (LMT) | Phase 3 | Hypercholesterolemia | - | - |
Lunsekimig | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
telithromycin (HMR3647) | Phase 3 | Infections | - | - |
Clopidogrel (SR25990) | Phase 3 | Acute Coronary Syndromes | - | - |
Vandetanib | Phase 3 | Thyroid Neoplasms | - | - |
Lactic Acid | Phase 3 | Hygiene | - | - |
Sarilumab SAR153191 | Phase 3 | Corona Virus Infection | - | - |
Sevelamer carbonate (Renvela®) | Phase 3 | Chronic Kidney Disease | - | - |
Telithromycin | Phase 3 | Asthma | - | - |
Insulin glargine U100 (HOE901) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Granulocyte colony-stimulating factor plus plerixafor | Phase 3 | Multiple Myeloma | - | - |
clopidogrel (SR25990C) | Phase 3 | Platelet Aggregation Inhibitors | - | - |
Docetaxel (TAXOTERE®) Chemotherapy | Phase 3 | Prostatic Neoplasms | - | - |
Fitusiran | Phase 3 | Hemophilia | - | - |
Insulin glargine (HOE901) | Phase 3 | Type 2 Diabetes | - | - |
Itepekimab (SAR440340) | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | - | - |
insulin lispro | Phase 3 | Diabetes Mellitus, Insulin-Dependent | - | - |
gemcitabine | Phase 3 | Urinary Bladder Neoplasms | - | - |
Saredutant | Phase 3 | Depressive Disorder | - | - |
rilzabrutinib | Phase 3 | Immune Thrombocytopenia | - | - |
Tolebrutinib | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Insulin glulisine | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Rimonabant | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
sarilumab SAR153191 (REGN88) | Phase 3 | Rheumatoid Arthritis | - | - |
Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine | Phase 3 | Meningococcal Infection (Healthy Volunteers) | - | - |
Cisplatin | Phase 3 | Nasopharyngeal Neoplasms | - | - |
Dupilumab SAR231893 (REGN668) | Phase 3 | Asthma | - | - |
Saredutant succinate (SR48968C) | Phase 3 | Depressive Disorder | - | - |
Alemtuzumab | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
5-FLUOROURACIL | Phase 3 | Head and Neck Neoplasms | - | - |
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Phase 3 | Neoplasms | - | - |
Insulin glargine | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Duvakitug | Phase 3 | Crohn's Disease | - | - |
Xaliproden (SR57746A) | Phase 3 | Metastases | - | - |
SR48692 | Phase 3 | Lung Cancer | - | - |
efanesoctocog alfa (BIVV001) | Phase 3 | Factor VIII Deficiency | - | - |
gemcitabine/carboplatin | Phase 3 | Breast Cancer | - | - |
ZD6474 (vandetanib) | Phase 3 | Non-Small-Cell Lung Carcinoma | - | - |
Cabazitaxel (XRP6258) | Phase 3 | Prostate Cancer | - | - |
Enoxaparin sodium (XRP4563) | Phase 3 | Myocardial Infarction | - | - |
Artesunate + Amodiaquine | Phase 3 | Malaria | - | - |
Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix) | Phase 3 | Hygiene | - | - |
fexofenadine/Allegra (M016455) | Phase 3 | Rhinitis Perennial | - | - |
Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine | Phase 3 | Healthy Volunteers (Meningococcal Infection) | - | - |
MenACYW conjugate vaccine | Phase 3 | Meningococcal Immunisation | - | - |
Lipid Modifying Therapy (LMT) | Phase 3 | Hypercholesterolaemia | - | - |
tolevamer potassium-sodium (GT267-004) | Phase 3 | Pseudomembranous Colitis | - | - |
Aflibercept | Phase 3 | Colorectal Cancer Metastatic | - | - |
Iniparib | Phase 3 | Breast Cancer, Metastatic | - | - |
Influenza virus vaccine (split virion, inactivated) | Phase 3 | Influenza | - | - |
ALIROCUMAB SAR236553 (REGN727) | Phase 3 | Hypercholesterolemia | - | - |
dronedarone (SR33589) | Phase 3 | Atrial Fibrillation | - | - |
Amlitelimab | Phase 3 | Asthma | - | - |
Sitagliptin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Insulin glargine/Lixisenatide (HOE901/AVE0010) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
PCV21 | Phase 3 | Sickle Cell Disease | - | - |
Metformin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Clopidogrel | Phase 3 | Ischemia | - | - |
Teriflunomide (HMR1726) | Phase 3 | Multiple Sclerosis | - | - |
Insulin glargine/lixisenatide Fixed Ratio Combination | Phase 3 | Type 2 Diabetes | - | - |
Irbesartan | Phase 3 | Atrial Fibrillation | - | - |
teriflunomide HMR1726 | Phase 3 | Multiple Sclerosis | - | - |
Mitoxantrone | Phase 3 | Prostatic Neoplasms | - | - |
rhIDU (recombinant human-Alpha-L-Iduronidase) | Phase 3 | Mucopolysaccharidosis I | - | - |
escitalopram | Phase 3 | Major Depressive Disorder | - | - |
SR121463B | Phase 3 | Inappropriate ADH Syndrome | - | - |
Olipudase alfa | Phase 3 | Sphingomyelin Lipidosis | - | - |
Myozyme | Phase 3 | Glycogen Storage Disease Type II | - | - |
Itepekimab SAR440340 | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Insulin glulisine QD | Phase 3 | Type 2 Diabetes | - | - |
Enoxaparin sodium | Phase 3 | Percutaneous Coronary Intervention | - | - |
Ciclesonide (XRP1526) | Phase 3 | Asthma | - | - |
Yellow fever vaccine (live) | Phase 3 | Yellow Fever | - | - |
Dermacyd PH_DETINLYN (Lactic Acid) | Phase 3 | Hygiene | - | - |
Lixisenatide (AVE0010) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
LACTIC ACID(ND) | Phase 3 | Hygiene | - | - |
Insuline glulisine | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Rimonabant (SR141716) | Phase 3 | Obesity | - | - |
amibegron (SR58611A) | Phase 3 | Major Depressive Disorders | - | - |
Alfuzosin | Phase 3 | Prostatic Hyperplasia | - | - |
Eliglustat tartrate | Phase 3 | Gaucher Disease, Type 1 | - | - |
SR58611A | Phase 3 | Depressive Disorder | - | - |
Larotaxel (XRP9881) | Phase 3 | Pancreatic Neoplasms | - | - |
lactoserum | Phase 3 | Hygiene | - | - |
NVX-CoV2705 | Phase 3 | COVID-19 | - | - |
Lispro | Phase 3 | Diabetes Mellitus | - | - |
cabazitaxel (XRP6258) (RPR116258) | Phase 3 | Neoplasms | - | - |
Thyrogen + Radioiodine (131I) | Phase 3 | Thyroid Neoplasms | - | - |
alfuzosin (SL770499) | Phase 3 | Urinary Bladder Neurogenic | - | - |
Alirocumab | Phase 3 | Hypercholesterolemia | - | - |
ezetimibe | Phase 3 | Hypercholesterolemia | - | - |
Caplacizumab | Phase 3 | Acquired Thrombotic Thrombocytopenic Purpura | - | - |
Glimepiride | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
Docetaxel | Phase 3 | Lung Neoplasms | - | - |
Fexofenadine | Phase 3 | Asthma | - | - |
Dupilumab | Phase 3 | Chronic Spontaneous Urticaria | - | - |
Enoxaparin | Phase 3 | Venous Thromboembolism | - | - |
Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib | Phase 3 | Diphtheria | - | - |
leflunomide | Phase 3 | Arthritis, Rheumatoid | - | - |
Sarilumab | Phase 3 | Rheumatoid Arthritis | - | - |
Dupilumab SAR231893 | Phase 3 | Chronic Rhinosinusitis Without Nasal Polyps | - | - |
INSULIN GLARGINE (U300) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine | Phase 3 | Healthy Volunteers (Meningococcal Infection) | - | - |
Dermacyd PH_DETINBACK (Lactic Acid) | Phase 3 | Hygiene | - | - |
Isatuximab SAR650984 | Phase 3 | Plasma Cell Myeloma | - | - |
SAR3419 | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
XRP0038 (NV1FGF) | Phase 2 | Peripheral Arterial Occlusive Disease | - | - |
DOCETAXEL XRP6976 | Phase 2 | Squamous Cell Carcinoma of Head and Neck | - | - |
Inactivated, Split-Virion Influenza Virus | Phase 2 | Influenza | - | - |
Split, Inactivated, Trivalent Influenza Vaccine | Phase 2 | Orthomyxoviridae Infection | - | - |
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody | Phase 2 | Systemic Sclerosis | - | - |
Levofolinate | Phase 2 | Colorectal Cancer Metastatic | - | - |
clofarabine (IV formulation) | Phase 2 | Acute Myelogenous Leukemia | - | - |
Swine A/H1N1 influenza vaccine (split virion, inactivated) | Phase 2 | Influenza | - | - |
Liraglutide | Phase 2 | Type 2 Diabetes Mellitus | - | - |
ataciguat (HMR1766) | Phase 2 | Pain | - | - |
A/H5N1 inactivated, split-virion influenza virus | Phase 2 | Influenza | - | - |
Thymoglobulin [Anti-thymocyte Globulin (rabbit)] | Phase 2 | Cadaveric Donor Renal Transplantation | - | - |
RISEDRONATE | Phase 2 | OSTEOPOROSIS, POSTMENOPAUSAL | - | - |
Oxaliplatin (SR96669) | Phase 2 | Gastrointestinal Cancer | - | - |
plerixafor | Phase 2 | Ewing's Sarcoma/Soft Tissue Sarcoma | - | - |
G-CSF Plus Plerixafor | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
frexalimab | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |
XL147 (SAR245408) | Phase 2 | Breast Cancer | - | - |
Fluticasone/Salmeterol combination therapy | Phase 2 | Asthma | - | - |
SAR443122 | Phase 2 | Cutaneous Lupus Erythematosus | - | - |
Alglucosidase alfa | Phase 2 | Glycogen Storage Disease Type II | - | - |
Isatuximab | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Teplizumab | Phase 2 | Type 1 Diabetes Mellitus | - | - |
BSI-201 | Phase 2 | Ovarian Cancer | - | - |
Doxercalciferol | Phase 2 | Moderate to Severe Chronic Plaque Psoriasis | - | - |
Atorvastatin | Phase 2 | Hypercholesterolemia | - | - |
SSR149415 | Phase 2 | Anxiety Disorders | - | - |
venglustat (GZ402671) | Phase 2 | Gaucher Disease Type 1 | - | - |
SAR245409 | Phase 2 | Lymphoma | - | - |
ILX651 | Phase 2 | Hormone-refractory Prostate Cancer | - | - |
cabazitaxel XRP6258 | Phase 2 | Gastric Cancer | - | - |
Inactivated, split-virion influenza vaccine | Phase 2 | Influenza | - | - |
Avalglucosidase Alfa | Phase 2 | Glycogen Storage Disease Type II Pompe Disease | - | - |
SAR156597 | Phase 2 | Systemic Sclerosis | - | - |
Ad2/HIF-1α/VP16 | Phase 2 | Intermittent Claudication | - | - |
SR57667B | Phase 2 | Parkinson Disease | - | - |
Oxaliplatin | Phase 2 | Stomach Neoplasms | - | - |
Belumosudil | Phase 2 | Chronic Graft Versus Host Disease | - | - |
RSVt Vaccine | Phase 2 | Respiratory Syncytial Virus Infection | - | - |
Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine | Phase 2 | Meningitis | - | - |
Acne mRNA vaccine | Phase 2 | Acne | - | - |
SAR441566 | Phase 2 | Psoriasis | - | - |
Fabrazyme (agalsidase beta) | Phase 2 | Fabry Disease | - | - |
satavaptan (SR121463B) | Phase 2 | Ascites | - | - |
eplivanserin (SR46349) | Phase 2 | Fibromyalgia | - | - |
ombrabulin (AVE8062) | Phase 2 | Non-small Cell Lung Cancer | - | - |
Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant | Phase 2 | Influenza | - | - |
Oxaliplatin, 5-FU | Phase 2 | Head and Neck Cancer | - | - |
rasburicase (SR29142) | Phase 2 | Nutritional and Metabolic Diseases | - | - |
Fludarabine Phosphate (Fludara) | Phase 2 | Non Hodgkin Lymphoma | - | - |
GZ/SAR402671 | Phase 2 | Fabry Disease | - | - |
Influenza Virus Vaccine USP Trivalent Types A and B | Phase 2 | Influenza | - | - |
ZD6474, Vandetanib | Phase 2 | Biliary Tract Cancer | - | - |
Mometasone furoate nasal spray | Phase 2 | Nasal Polyps | - | - |
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) | Phase 2 | Mucopolysaccharidosis I | - | - |
ATN-103 | Phase 2 | Active Rheumatoid Arthritis | - | - |
CYD Dengue Vaccine | Phase 2 | Dengue | - | - |
plerixafor GZ316455 | Phase 2 | Lymphoma | - | - |
clofarabine | Phase 2 | Acute Myelogenous Leukemia | - | - |
Sevelamer carbonate | Phase 2 | Hyperphosphatemia | - | - |
Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine | Phase 2 | Lung Neoplasms | - | - |
Capecitabine | Phase 2 | Rectal Neoplasms | - | - |
SAR442970 | Phase 2 | Ulcerative Colitis | - | - |
Nerispirdine | Phase 2 | Multiple Sclerosis | - | - |
ZD6474 | Phase 2 | Breast Neoplasms | - | - |
Methotrexate | Phase 2 | Rheumatoid Arthritis | - | - |
ALX-0061 | Phase 2 | Rheumatoid Arthritis | - | - |
docetaxel (XRP6976) | Phase 2 | Therapy, Prostatic Neoplasms | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Sanofi's drug pipeline?→
CatalystAlert tracks 186 drug candidates in Sanofi's (SNYNF) pipeline across Phase 3, Phase 2. Its lead program is SSR591813L (dianicline) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sanofi's next FDA catalyst?→
Sanofi's (SNYNF) next tracked catalyst is a Phase 2 expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SNYNF biotech catalysts?→
Add SNYNF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sanofi's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.